Trial record 1 of 7 for:    medimmune tralokinumab
Previous Study | Return to List | Next Study

A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis

This study has been terminated.
Sponsor:
Information provided by (Responsible Party):
MedImmune LLC
ClinicalTrials.gov Identifier:
NCT01629667
First received: June 12, 2012
Last updated: February 29, 2016
Last verified: February 2016
  Purpose
To study the safety and effectiveness of multiple-doses of tralokinumab on pulmonary function in adults with mild to moderate idiopathic pulmonary fibrosis (IPF). IPF is a chronic, progressive, irreversible, and usually fatal lung disease of unknown cause.

Condition Intervention Phase
Idiopathic Pulmonary Fibrosis
Biological: Tralokinumab
Other: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis

Resource links provided by NLM:


Further study details as provided by MedImmune LLC:

Primary Outcome Measures:
  • Change from Baseline in Percent-Predicted Forced Vital Capacity at Week 52 [ Time Frame: Week 52 ] [ Designated as safety issue: No ]
    Mean change from baseline in percent-predicted forced vital capacity


Secondary Outcome Measures:
  • Number of Participants with Adverse Events [ Time Frame: Day 1 - Week 88 ] [ Designated as safety issue: Yes ]
    Number and percent of subjects with at least one treatment-emergent adverse event

  • Number of Participants with Disease Progression [ Time Frame: Day 1 - Week 88 ] [ Designated as safety issue: No ]
    Number and percent of subjects who have documented disease progression

  • Mean Tralokinumab Serum Concentration [ Time Frame: Day 1 - Week 88 ] [ Designated as safety issue: No ]
    Mean serum concentration of tralokinumab

  • Number of Participants with Serious Adverse Events [ Time Frame: Day 1 - Week 88 ] [ Designated as safety issue: Yes ]
    Number and percent of subjects with at least one treatment-emergent serious adverse event

  • Number of Participants with Clinically Significant Electrocardiogram Abnormalities [ Time Frame: Day 1 - Week 88 ] [ Designated as safety issue: Yes ]
    Number and percent of subjects with at least one clinically significant electrocardiogram abnormality

  • Number of Participants with Clinically Significant Vital Sign Abnormalities [ Time Frame: Day 1 - Week 88 ] [ Designated as safety issue: Yes ]
    Number and percent of subjects with at least one clinically significant vital sign abnormality

  • Number of Participants with Clinically Significant Laboratory Abnormalities [ Time Frame: Day 1 - Week 88 ] [ Designated as safety issue: Yes ]
    Number and percent of subjects with at least one clinically significant laboratory abnormality

  • Change from Baseline in Diffusion Capacity for Carbon Monoxide at Weeks 36, 52, and 72 [ Time Frame: Weeks 36, 52, and 72 ] [ Designated as safety issue: No ]
    Mean change from baseline in percent-predicted diffusion capacity for carbon monoxide at Weeks 36, 52, and 72

  • Change from Baseline in Lung Volumes at Weeks 36, 52, and 72 [ Time Frame: Weeks 36, 52, and 72 ] [ Designated as safety issue: No ]
    Mean change from baseline in lung volumes (total lung capacity, residual volume, vital capacity, functional residual capacity, and inspiratory capacity) at Weeks 36, 52, and 72

  • Number of Participants with a Decline in the 6 Minute Walk Test [ Time Frame: Day 1 - Week 88 ] [ Designated as safety issue: No ]
    Number and percent of subjects with a decline in the 6 Minute Walk Test greater than or equal to 50 meters

  • Change from Baseline in Oxygen Saturation by Pulse Oximetry During the Study [ Time Frame: Day 1 - Week 88 ] [ Designated as safety issue: No ]
    Mean change from baseline in oxygen saturation by pulse oximetry

  • Number of Participants with Exacerbations of Idiopathic Pulmonary Fibrosis [ Time Frame: Day 1 - Week 88 ] [ Designated as safety issue: No ]
    Number and percent of subjects with at least one exacerbation of idiopathic pulmonary fibrosis

  • Change from Baseline in Lung Function During the Study [ Time Frame: Day 1 - Week 88 ] [ Designated as safety issue: No ]
    Mean change from baseline in lung function (forced expiratory volume in 1 second and forced vital capacity).

  • Mean Clinical Global Impression of Severity Scores [ Time Frame: Day 1 - Week 88 ] [ Designated as safety issue: No ]
    Mean Clinical Global Impression of Severity scores

  • Mean Clinical Global Impression of Change Scores [ Time Frame: Day 1 - Week 88 ] [ Designated as safety issue: No ]
    Mean Clinical Global Impression of Change score

  • Number of Participants with Positive Antibodies to Tralokinumab [ Time Frame: Day 1 - Week 88 ] [ Designated as safety issue: Yes ]
    Number and percent of subjects with positive antibodies to tralokinumab


Enrollment: 409
Study Start Date: October 2012
Study Completion Date: January 2016
Primary Completion Date: October 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Low dose
Investigational product tralokinumab
Biological: Tralokinumab
Tralokinumab is a human recombinant monoclonal antibody (MAb)) of the subclass that specifically binds human IL-13, blocking interactions with the IL-13 receptor
Experimental: High dose
Investigational product tralokinumab
Biological: Tralokinumab
Tralokinumab is a human recombinant monoclonal antibody (MAb)) of the subclass that specifically binds human IL-13, blocking interactions with the IL-13 receptor
Placebo Comparator: Placebo
Placebo
Other: Placebo

Detailed Description:
The primary objective of this study is to determine the effect of multiple doses of tralokinumab on pulmonary function in adults with mild to moderate IPF
  Eligibility

Ages Eligible for Study:   50 Years to 79 Years   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • 1) IPF diagnosis for ≤ 5 years prior to Visit 1 (screening). Confirmation of diagnosis of IPF in accordance is required for subject inclusion 2) Confirmed diagnosis of IPF by clinical characteristics, HRCT and surgical lung biopsy (if required) 3)Mild to moderate IPF to include all of the following at screening:

    1. FVC ≥ 50% predicted normal
    2. Partial pressure of oxygen in arterial blood (PaO2) of ≥ 55 mmHg on room air or 50 mmHg at high altitude (> 1500 meters), or oxygen saturation by pulse oximetry (SpO2) of ≥ 90%on room air at rest
    3. Hemoglobin-corrected diffusion capacity for carbon monoxide (DLCO) ≥ 30% predicted normal 4) Be able to walk ≥ 100 meters unassisted

Key Exclusion Criteria:

  1. A FEV1/FVC ratio less than 0.70 at the time of screening (postbronchodilator)
  2. The extent of emphysema on the HRCT is greater than the extent of fibrosis.
  3. Currently listed for lung transplantation
  4. Use of the following medications:

    1. Immunosuppressive medications (eg, methotrexate, cyclosporine, azathioprine, intramuscular long-acting depot corticosteroid) within 3 months prior to Visit 1 (screening). Oral prednisone ≤ 15 mg/day (or equivalent oral corticosteroid) is allowed for chronic use if subject was on a stable dose at least 30 days prior to Visit 1 (screening)
    2. Pirfenidone within 4 weeks prior to Visit 1 (screening)
    3. N-acetylcysteine within 4 weeks prior to Visit 1 (screening)
    4. Live attenuated vaccines within 4 weeks prior to Visit 1 (screening)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01629667

  Hide Study Locations
Locations
United States, Arizona
Research Site
Phoenix, Arizona, United States
United States, California
Research Site
La Jolla, California, United States
Research Site
Sacramento, California, United States
United States, Florida
Research Site
Tampa, Florida, United States
Research Site
Winter Park, Florida, United States
United States, Georgia
Research Site
Atlanta, Georgia, United States
United States, Hawaii
Research Site
Honolulu, Hawaii, United States
United States, Illinois
Research Site
Chicago, Illinois, United States
United States, Kentucky
Research Site
Louisville, Kentucky, United States
United States, Michigan
Research Site
Ann Arbor, Michigan, United States
United States, Minnesota
Research Site
Rochester, Minnesota, United States
United States, Missouri
Research Site
Chesterfield, Missouri, United States
United States, New Jersey
Research Site
Summit, New Jersey, United States
United States, North Carolina
Research Site
Durham, North Carolina, United States
United States, Pennsylvania
Research Site
Hershey, Pennsylvania, United States
Research Site
Philadelphia, Pennsylvania, United States
United States, South Carolina
Research Site
Charleston, South Carolina, United States
United States, Tennessee
Research Site
Nashville, Tennessee, United States
United States, Texas
Research Site
McAllen, Texas, United States
Research Site
McKinney, Texas, United States
United States, Utah
Research Site
Salt Lake City, Utah, United States
Australia
Research Site
Box Hill, Australia
Research Site
Camperdown, Australia
Research Site
Concord, Australia
Research Site
Darlinghurst, Australia
Research Site
Frankston, Australia
Research Site
Glen Osmond, Australia
Research Site
New Lambton, Australia
Research Site
Parkville, Australia
Research Site
Prahran, Australia
Research Site
Woodville South, Australia
Canada, Alberta
Research Site
Edmonton, Alberta, Canada
Canada, British Columbia
Research Site
Vancouver, British Columbia, Canada
Canada, Ontario
Research Site
Windsor, Ontario, Canada
Canada, Quebec
Research Site
Montreal, Quebec, Canada
Canada
Research Site
Quebec, Canada
Israel
Research Site
Ashkelon, Israel
Research Site
Haifa, Israel
Research Site
Jerusalem, Israel
Research Site
Petach Tikva, Israel
Research Site
Rehovot, Israel
Research Site
Tel Aviv, Israel
Korea, Republic of
Research Site
Seoul, Korea, Republic of
Peru
Research Site
Cercado de Lima, Peru
Research Site
Lima, Peru
Sponsors and Collaborators
MedImmune LLC
Investigators
Study Director: Joseph Parker, MD MedImmune LLC
  More Information

Responsible Party: MedImmune LLC
ClinicalTrials.gov Identifier: NCT01629667     History of Changes
Other Study ID Numbers: CD-RI-CAT-354-1066 
Study First Received: June 12, 2012
Last Updated: February 29, 2016
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Fibrosis
Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Idiopathic Interstitial Pneumonias
Pathologic Processes
Lung Diseases
Respiratory Tract Diseases
Lung Diseases, Interstitial
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on August 28, 2016